Nihon Kohden Corp
TSE:6849
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| JP |
|
Nihon Kohden Corp
TSE:6849
|
265B JPY |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
196.7B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
173.6B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
147B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
124.2B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
110.6B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
45.7B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
50.6B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
49.3B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
50.3B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
37.4B USD |
Loading...
|
Market Distribution
| Min | -179.8% |
| 30th Percentile | 21.8% |
| Median | 30.6% |
| 70th Percentile | 42.3% |
| Max | 18 197.9% |
Other Profitability Ratios
Nihon Kohden Corp
Glance View
Nihon Kohden Corp., founded in 1951, has evolved into a pioneering force in the medical technology landscape, blending innovation with a storied heritage. This Tokyo-based firm established its foothold by developing advanced medical electronic devices, initially focusing on EEG (electroencephalography) machines. As medical science rapidly advanced, Nihon Kohden expanded its portfolio to include a range of diagnostic and monitoring equipment. Today, the company's product line encompasses patient monitors, defibrillators, electrocardiographs, and clinical information systems, serving various healthcare domains. This focus on critical care and diagnostics creates consistent demand across global hospitals and clinics, reinforcing its reputation as a dependable partner in medical excellence. Financially, Nihon Kohden's business model thrives on a dual revenue structure: product sales and after-sales service. By manufacturing and distributing complex equipment directly and through a network of distributors, the company captures a significant share of initial capital expenditure in healthcare institutions. Furthermore, it enhances this income by offering ongoing equipment maintenance, training, and customer support, forming long-term relationships with healthcare providers. These services ensure not only a steady revenue stream beyond the initial sale but also brand loyalty and trust in an industry where precision and reliability are paramount. As it continues to innovate, Nihon Kohden's commitment to addressing the evolving needs of healthcare practitioners fortifies its market position and operational success.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Nihon Kohden Corp is 51.9%, which is above its 3-year median of 51.3%.
Over the last 3 years, Nihon Kohden Corp’s Gross Margin has increased from 51.3% to 51.9%. During this period, it reached a low of 49.6% on Jun 30, 2024 and a high of 53.1% on Jun 30, 2025.